Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Capital Expenditures: 2010-2025

Historic Capital Expenditures for Anika Therapeutics (ANIK) over the last 13 years, with Sep 2025 value amounting to $1.9 million.

  • Anika Therapeutics' Capital Expenditures rose 55.18% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.5 million, marking a year-over-year decrease of 9.46%. This contributed to the annual value of $7.7 million for FY2024, which is 42.51% up from last year.
  • Per Anika Therapeutics' latest filing, its Capital Expenditures stood at $1.9 million for Q3 2025, which was up 28.63% from $1.5 million recorded in Q2 2025.
  • In the past 5 years, Anika Therapeutics' Capital Expenditures ranged from a high of $3.4 million in Q2 2024 and a low of $570,000 during Q1 2021.
  • In the last 3 years, Anika Therapeutics' Capital Expenditures had a median value of $1.5 million in 2025 and averaged $1.8 million.
  • In the last 5 years, Anika Therapeutics' Capital Expenditures soared by 1,068.65% in 2021 and then slumped by 56.89% in 2025.
  • Over the past 5 years, Anika Therapeutics' Capital Expenditures (Quarterly) stood at $1.1 million in 2021, then spiked by 124.40% to $2.5 million in 2022, then declined by 27.24% to $1.8 million in 2023, then decreased by 28.97% to $1.3 million in 2024, then soared by 55.18% to $1.9 million in 2025.
  • Its last three reported values are $1.9 million in Q3 2025, $1.5 million for Q2 2025, and $2.8 million during Q1 2025.